{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:27:07Z","timestamp":1787851627779,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":148,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014261","name":"NIHCM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Public Economics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jpubeco.2026.105595","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:09:18Z","timestamp":1771564158000},"page":"105595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lagged-price reimbursement contracts: The impact of medicare Part B on pharmaceutical price growth"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-2927","authenticated-orcid":false,"given":"Angelique","family":"Acquatella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Marzilli","family":"Ericson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Starc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpubeco.2026.105595_bib0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2307\/2696361","article-title":"Incentives versus transaction costs: a theory of procurement Contracts","volume":"32","author":"Bajari","year":"2001","journal-title":"RAND J. Econ."},{"issue":"4","key":"10.1016\/j.jpubeco.2026.105595_bib0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1257\/aer.20200738","article-title":"Public procurement in law and practice","volume":"112","author":"Bosio","year":"2022","journal-title":"Am. Econ. Rev."},{"key":"10.1016\/j.jpubeco.2026.105595_bib0015","unstructured":"Centers for Medicare & Medicaid Services (CMS), 2006\u20132019. ASP pricing files. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"issue":"1","key":"10.1016\/j.jpubeco.2026.105595_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/689772","article-title":"In the shadow of a giant: Medicare\u2019s influence on private physician payments","volume":"125","author":"Clemens","year":"2017","journal-title":"J. Polit. Econ."},{"issue":"1","key":"10.1016\/j.jpubeco.2026.105595_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2307\/2555956","article-title":"The efficiency of incomplete contracts: an empirical analysis of air force engine procurement","volume":"24","author":"Crocker","year":"1993","journal-title":"RAND J. Econ."},{"issue":"9","key":"10.1016\/j.jpubeco.2026.105595_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.3630","article-title":"Medicare enters the pharmaceutical purchasing business","volume":"3","author":"Cutler","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.jpubeco.2026.105595_bib0035","series-title":"Stocking under the influence: spillovers from commercial drug coverage to medicare utilization","author":"Dean","year":"2023"},{"issue":"4","key":"10.1016\/j.jpubeco.2026.105595_bib0040","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1257\/aer.20130903","article-title":"Medicare part d: are insurers gaming the low income subsidy design?","volume":"105","author":"Decarolis","year":"2015","journal-title":"Am. Econ. Rev."},{"issue":"6","key":"10.1016\/j.jpubeco.2026.105595_bib0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMsa1706475","article-title":"Consequences of the 340B drug pricing program","volume":"378","author":"Desai","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpubeco.2026.105595_bib0050","article-title":"Bargaining and international reference pricing in the pharmaceutical industry","volume":"30053","author":"Dubois","year":"2022","journal-title":"Natl. Bur. Econ. Res. Work. Pap."},{"issue":"1","key":"10.1016\/j.jpubeco.2026.105595_bib0055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1257\/aer.100.1.590","article-title":"The effect of medicare part D on pharmaceutical prices and utilization","volume":"100","author":"Duggan","year":"2010","journal-title":"Am. Econ. Rev."},{"key":"10.1016\/j.jpubeco.2026.105595_bib0060","first-page":"545","article-title":"Developing a framework for decomposing medical-care expenditure growth: exploring issues of representativeness","author":"Dunn","year":"2014"},{"issue":"1","key":"10.1016\/j.jpubeco.2026.105595_bib0065","first-page":"38","article-title":"Consumer inertia and firm pricing in the Medicare Part D prescription drug insurance exchange","volume":"6","author":"Ericson","year":"2014","journal-title":"Am. Econ. J.: Econ. Policy"},{"issue":"1","key":"10.1016\/j.jpubeco.2026.105595_bib0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2307\/2555402","article-title":"Dynamic competition with switching costs","volume":"19","author":"Farrell","year":"1988","journal-title":"RAND J. Econ."},{"issue":"6","key":"10.1016\/j.jpubeco.2026.105595_bib0075","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1257\/aer.20210208","article-title":"Optimal contracting with altruistic agents: medicare payments for dialysis drugs","volume":"113","author":"Gaynor","year":"2023","journal-title":"Am. Econ. Rev."},{"key":"10.1016\/j.jpubeco.2026.105595_bib0080","series-title":"USC-Brookings Schaeffer Initiative for Health Policy Working Paper","article-title":"Medicare payment for physician-administered (Part B) drugs","author":"Ginsburg","year":"2021"},{"issue":"1","key":"10.1016\/j.jpubeco.2026.105595_bib0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the Market for Anticancer Drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J. Econ. Perspect."},{"issue":"4","key":"10.1016\/j.jpubeco.2026.105595_bib0090","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/1475-6773.14139","article-title":"The influence of Medicare Part D on the list pricing of brand drugs","volume":"58","author":"Ippolito","year":"2023","journal-title":"Health Serv. Res."},{"issue":"7","key":"10.1016\/j.jpubeco.2026.105595_bib0095","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1377\/hlthaff.2009.0563","article-title":"How Medicare\u2019s payment cuts for cancer chemotherapy drugs changed patterns of treatment","volume":"29","author":"Jacobson","year":"2010","journal-title":"Health Aff."},{"key":"10.1016\/j.jpubeco.2026.105595_bib0100","series-title":"Working Paper","article-title":"The dynamic effects of health care price reform","author":"Yunan","year":"2023"},{"issue":"3","key":"10.1016\/j.jpubeco.2026.105595_bib0105","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/restud\/rdab051","article-title":"Winning by default: why is there so little competition in government procurement?","volume":"89","author":"Kang","year":"2022","journal-title":"Rev. Econ. Stud."},{"issue":"1","key":"10.1016\/j.jpubeco.2026.105595_bib0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/joie.12036","article-title":"Price adjustment policies in procurement contracting: an analysis of bidding behavior","volume":"62","author":"Kosmopoulou","year":"2014","journal-title":"J. Ind. Econ."},{"issue":"6","key":"10.1016\/j.jpubeco.2026.105595_bib0115","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1257\/aer.101.6.2653","article-title":"Bid preference programs and participation in highway procurement auctions","volume":"101","author":"Krasnokutskaya","year":"2011","journal-title":"Am. Econ. Rev."},{"issue":"2","key":"10.1016\/j.jpubeco.2026.105595_bib0120","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1257\/jel.20161327","article-title":"Economics of the Pharmaceutical Industry","volume":"56","author":"Lakdawalla","year":"2018","journal-title":"J. Econ. Lit."},{"issue":"2","key":"10.1016\/j.jpubeco.2026.105595_bib0125","first-page":"345","article-title":"Reference pricing as a deterrent to entry: evidence from the European pharmaceutical market","volume":"15","author":"Maini","year":"2023","journal-title":"Am. Econ. J.: Microecon."},{"key":"10.1016\/j.jpubeco.2026.105595_bib0130","first-page":"461","article-title":"Physician agency","author":"McGuire","year":"2000"},{"key":"10.1016\/j.jpubeco.2026.105595_bib0135","series-title":"June 2016 report to the congress: medicare and the health care delivery system","year":"2016"},{"key":"10.1016\/j.jpubeco.2026.105595_bib0140","series-title":"Report to the Congress: medicare and the health care delivery system, chapter 5","year":"2016"},{"key":"10.1016\/j.jpubeco.2026.105595_bib0145","series-title":"MedPAC July 2022 Data Book, Section 10: Prescription drugs","year":"2022"},{"key":"10.1016\/j.jpubeco.2026.105595_bib0150","series-title":"Hutchins Center Working Paper 30","article-title":"Enabling competition in pharmaceutical markets","author":"Morton","year":"2017"},{"issue":"1","key":"10.1016\/j.jpubeco.2026.105595_bib0155","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.14694\/EdBook_AM.2015.35.e75","article-title":"Reform of the buy-and-bill system for outpatient chemotherapy care is inevitable: perspectives from an economist, a realpolitik, and an oncologist","volume":"35","author":"Polite","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"5","key":"10.1016\/j.jpubeco.2026.105595_bib0160","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1162\/rest_a_00849","article-title":"Does medicare reimbursement drive up drug launch prices?","volume":"102","author":"Ridley","year":"2020","journal-title":"Rev. Econ. Stat."},{"key":"10.1016\/j.jpubeco.2026.105595_bib0165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijindorg.2016.11.004","article-title":"Regulation of price increases","volume":"50","author":"Ridley","year":"2017","journal-title":"Int. J. Ind. Organ."},{"issue":"2","key":"10.1016\/j.jpubeco.2026.105595_bib0170","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3368\/jhr.50.2.301","article-title":"What are we weighting for?","volume":"50","author":"Solon","year":"2015","journal-title":"J. Hum. Resour."},{"issue":"2","key":"10.1016\/j.jpubeco.2026.105595_bib0175","first-page":"348","article-title":"The role of government reimbursement in drug shortages","volume":"9","author":"Yurukoglu","year":"2017","journal-title":"Am. Econ. J.: Econ. Policy"}],"container-title":["Journal of Public Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0047272726000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0047272726000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:01:04Z","timestamp":1787850064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0047272726000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"alternative-id":["S0047272726000319"],"URL":"https:\/\/doi.org\/10.1016\/j.jpubeco.2026.105595","relation":{},"ISSN":["0047-2727"],"issn-type":[{"value":"0047-2727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lagged-price reimbursement contracts: The impact of medicare Part B on pharmaceutical price growth","name":"articletitle","label":"Article Title"},{"value":"Journal of Public Economics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpubeco.2026.105595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105595"}}